Targeted cancer drugs have helped many patients live longer and healthier lives, but researchers still aren't sure why some of these drugs work in certain patients and not in others, says Technology Review's Emily Singer. Researchers are starting to learn more about how the drugs work by examining the inner workings of cancer cells, which could enable a new approach to personalized treatment — specific combinations of drugs that would more effectively treat a patient's cancer, Singer adds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.